Global G-CSF Granulocyte Colony Stimulating Factors Market Opportunities And Strategies 2023
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
The Business Research Company’s G-CSF granulocyte colony stimulating factors market report forecasts the G-CSF granulocyte colony stimulating factors market size to grow to $9.94 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.
Learn More On The G-CSF Granulocyte Colony Stimulating Factors Market Report 2023 – https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report
G-CSF Granulocyte Colony Stimulating Factors Market Size Forecast
The global G-CSF granulocyte colony stimulating factors market is expected to grow from $7.99 billion in 2022 to $8.43 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The G-CSF (granulocyte colony stimulating factors) market is expected to grow from $9.94 billion in 2027 at a CAGR of 4.2%.
North America held the largest G-CSF granulocyte colony stimulating factors market share.
Key G-CSF Granulocyte Colony Stimulating Factors Market Driver – Increase In The Prevalence Of Cancer
For example, according to the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency that publishes cancer research and data, 28.4 million new cases of cancer will be diagnosed worldwide in 2040, up 47% from the anticipated 19.3 million cases in 2020, owing primarily to population growth and ageing. G-CSF is a type of growth factor that stimulates the production of white blood cells in the bone marrow to reduce the risk of infection and sepsis. G-CSF speeds recovery and lowers mortality from neutropenia following cancer chemotherapy in cancer patients. It can also help to prevent infections following certain types of cancer treatment. As a result, the rising occurrence of cancer is likely to propel the G-CSF market forward.
Request for A Sample Of The Global G-CSF Granulocyte Colony Stimulating Factors Market Report:
Key G-CSF Granulocyte Colony Stimulating Factors Market Trend – Strategic Collaborations For Developing Innovative Products
Strategic alliances are being pursued by companies in the G-CSF industry in order to produce innovative products and increase market share. While firms have traditionally partnered with one another as well as academic and research organisations in this industry through partnerships, the number of in or out-licensing arrangements has increased in recent years. For example, in 2022, Evive Biotech, a Singapore-based biopharmaceutical business, entered into an exclusive long-term licence arrangement with APOGEPHA, a German pharmaceutical company, for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is a new dimeric G-CSF long-acting fusion protein that has not been pegylated.
G-CSF Granulocyte Colony Stimulating Factors Market Segment
1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)
2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Other Applications
3) By Product: Tablet, Capsule, Other Products
G-CSF Granulocyte Colony Stimulating Factors Market Major Players and Strategies
Major players in the G-CSF granulocyte colony stimulating factors market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, StadaArzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy’s Laboratories, and Celltrion Inc.
Novartis AG, a Swiss pharmaceutical corporation specialising in the research, development, production, and commercialization of pharmaceuticals, paid $800 million for Gyroscope Therapeutics Holdings plc in December 2021. G-CSF medications would be added to Novartis’ portfolio, enhancing gene therapy research capabilities and delivering ophthalmic innovation to treat and prevent blindness around the world. Gyroscope Therapeutics Holdings plc is a clinical stage biopharmaceutical firm situated in the United Kingdom that is a pioneer in the discovery and development of biosimilars for the treatment of eye ailments.
The G-CSF Granulocyte Colony Stimulating Factors Global Market Report 2023 covers regional data on G-CSF granulocyte colony stimulating factors market size, G-CSF granulocyte colony stimulating factors market trends and drivers, opportunities, strategies, and G-CSF granulocyte colony stimulating factors market competitor analysis. The countries covered in the G-CSF granulocyte colony stimulating factors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
G-CSF (granulocyte colony stimulating factors) is a type of colony-stimulating factor that promotes the production of white blood cells in the bone marrow. G-CSF is given to patients who have particular malignancies, neutropenia caused by some forms of chemotherapy, or severe chronic neutropenia unrelated to cancer treatment. It is also known as filgrastim and Granulocyte Colony-Stimulating Factor.
View More Reports Related To The G-CSF Granulocyte Colony Stimulating Factors Market –
Gastrointestinal Devices Global Market Report 2023
Gastrointestinal Bleeding Treatment Devices Global Market Report 2023
Endoscopy Devices And Equipment Global Market Report 2023
Follow us on:
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: